Boehringer files Humira biosimilar in EU, US
Boehringer Ingeheim’s biosimilar to AbbVie’s mega blockbuster Humira has been accepted for review on both sides of the Atlantic, after having shown comparability in late-stage trials.
Read More
Tag: BI 695501
- UCB and Cancer Research UK form expanded alliance to advance novel cancer therapies
- Calla Lily Clinical Care begins dosing in trial of intravaginal platform for threatened miscarriage
- Palisade Bio reports phase 1a/b data showing colon‑targeted exposure
- MimiVax and Roswell Park open phase 2 trial of SurVaxM for metastatic neuroendocrine tumours
- Myomaker Bio unveils lab‑grown human muscle platform to transform drug testing
